ObesityWeek 2024. Semaglutide 2.4 mg reduces rates of composite CV outcomes in high-risk patients without diabetes and now is shown to reduce inpatient care and length of stay.
Novo Nordisk plans to file for regulatory approval this year of an expanded label for oral semaglutide, with an indication for reduction of MACE in high-risk adults with T2D.
Women remain underrepresented in heart disease research after decades of efforts to correct the balance, affecting trial data and women's cardiovascular care.
Prior SARS-CoV-2 infection was associated with a 2-fold increased risk for MACE for up to 3 years, even among people with no history of CVD, in a new analysis of UK Biobank data.